Article
AAV Kills Dividing Cells by Depleting PARP1 and Other DNA Damage Response Proteins
2025-10-15
Abstract excerpt
Recombinant adeno-associated virus (rAAV) is a replication-defective viral vector used in hundreds of human gene therapy trials, resulting in five FDA-approved therapies. Despite this success, rAAV-based gene therapies suffer from dose-limiting toxicities, resulting in several severe adverse reactions, including death. Previously, we discovered that rAAV rapidly kills mouse NPCs in vitro and in vivo. This vector c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 722e9f49-7a2c-5544-b07e-933cc2069e4c
- DOI
- 10.1101/2025.10.14.682484
